European Archives - Page 457 of 1443 - European Medical Journal

Gold crown on blue background

Could Eli Lilly take the crown in the obesity market?

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

African American Men Respond Better to Ra-223 Treatment

African American men with mCRPC may experience better outcomes than white men when treated with radium-223 dichloride.

Human versus Machine: Navigating Clinical Safety

In this episode, Jonathan Sackier sits down with Tom Bradshaw to explore the rapidly evolving landscape of digital health. They discuss Bradshaw’s expertise in the clinical application of AI and digital technologies, his work with the NHS and private sector firms, and more.

Cutting Blood Loss: Hypovolaemic Phlebotomy in Liver Surgery

The study’s findings demonstrate that hypovolaemic phlebotomy effectively reduces the need for red blood cell transfusions.

Improving Gestational Diabetes Diagnosis Through Enhanced Glucose Processing

Enhanced glucose processing during oral glucose tolerance testing significantly improves the accuracy and equity of gestational diabetes diagnosis.

New Metric Offers Insight into Red Blood Cell Function and Quality

A recent study has introduced FlowScore, a new metric for evaluating the quality of red blood cells that goes beyond traditional haemoglobin assays…

Avacopan Therapy Linked to Liver Injury in Patients With Vasculitis

Avacopan therapy for vasculitis carries a risk of liver injury, particularly in elderly and low-weight patients, highlighting the need for regular monitoring.

Hema Now: Episode 7: Decoding T Cells and Advancing Immunology

This week, Jonathan is joined by Shahram Kordasti, Associate Professor in Applied Cancer Immunopathology at King’s College London, UK.

Researchers

Gene therapy from Novartis shows promise for children with SMA

Novartis’ Phase III study has demonstrated significant improvement in motor function in children and young adults with spinal muscular atrophy

Steroid Use Linked to Long-Term Coronary Microvascular Dysfunction

AAS use may cause persistent coronary microvascular dysfunction, even years after cessation, highlighting long-term cardiovascular risks.